开盘$11.26
昨收$11.10
当日区间$11.02 – $11.40
成交量4.40M
市值$1.59B
市盈率（TTM）–
股息率–
NTLA 相关新闻
匹配 Intellia Therapeutics 或代码 NTLA 的头条新闻，按最新排序。
- Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target 正面
- H.C. Wainwright Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $25
- Intellia Therapeutics | 8-K: Current report
- Wedbush Initiates Intellia Therapeutics(NTLA.US) With Hold Rating, Announces Target Price $13
- Intellia Therapeutics Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
- Wedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral Rating
- Tracking Cathie Wood: Added over 110,000 shares of gene-editing firm NTLA, while continuing to reduce holdings and optimize portfolio allocation.
- BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $17 负面
- CCORF Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $49
- Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9
- Evercore Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $24
- A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25
- JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $29
- Morgan Stanley Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Maintains Target Price $15
- Wolfe Research Downgrades Intellia Therapeutics(NTLA.US) to Sell Rating, Announces Target Price $9 负面
暂无评论——快来第一个聊聊 NTLA。
登录后参与讨论。